Seeking Alpha

Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National...

Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases to conduct a Phase I study with its experimental flu vaccine and lead drug candidate, AVI-7100. The drug has  the potential to address a broad-spectrum of influenza viruses, including Tamiflu-resistant virus strains. Separately, The Street's Adam Feuerstein called the stock a top biotech pick for 2013, saying its Duchenne muscular dystrophy treatment, eteplirsen, and is poised for accelerated approval.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs